Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients

NCT00158860 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00158860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00158860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
June 21, 2004
Completion date
July 26, 2006
Enrollment
384 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

herpes genitalis